Armstrong Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Armstrong Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-32	Closed	-$14.2K	–	992
2025 Q2	$14.2K	Sell	32 -24	-43%	-$11.1K	﹤0.01%	598
2025 Q1	$22.6K	Hold	56	–	–	﹤0.01%	494
2024 Q4	$22.6K	Hold	56	–	–	﹤0.01%	494
2024 Q3	$26K	Sell	56 -41	-42%	-$19.7K	﹤0.01%	462
2024 Q2	$45.5K	Buy	97 +48	+98%	+$20.8K	﹤0.01%	368
2024 Q1	$19.9K	Hold	49	–	–	﹤0.01%	482
2023 Q4	$19.9K	Hold	49	–	–	﹤0.01%	482
2023 Q3	$17K	Hold	49	–	–	﹤0.01%	522
2023 Q2	$17.2K	Sell	49 -166	-77%	-$55.9K	﹤0.01%	511
2023 Q1	$67.7K	Buy	215 +49	+30%	+$14.7K	0.01%	281
2022 Q4	$47.9K	Buy	+166	New	+$50.6K	0.01%	331

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Armstrong Advisory Group's VRTX Position: Q3 2025 in Review

Armstrong Advisory Group sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 32 shares — an estimated $14.2K sold.

Armstrong Advisory Group first reported a position in VRTX in Q4 2022 and held it in 11 quarters. The position peaked at $67.7K in Q1 2023. 1,523 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

Armstrong Advisory Group reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Armstrong Advisory Group sold 32 Vertex Pharmaceuticals shares in Q3 2025, an estimated $14.2K.
Armstrong Advisory Group first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 11 quarters.
Armstrong Advisory Group's Vertex Pharmaceuticals position peaked at $67.7K in Q1 2023.
1,523 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Armstrong Advisory Group's 13F filing for Q3 2025, filed 8 Oct 2025.